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C
hromatin is the fi  nal  fi  lter  of 
many of the cell’s signaling 
pathways, says Oliver Rando. 
How these signals ultimately unravel the 
complex structure of chromatin and access 
particular DNA fi  les is a problem he’d 
like to solve. His approach is not to look 
at individual genes and ask how they are 
regulated, but rather to look at the entire 
genome, or at least very 
large chunks of it, using 
microarrays.
Rando is a pioneer of 
this genomic scale  ap-
proach to chromatin analy-
sis and has already pub-
lished a large number of 
papers on the subject, de-
spite being only at the 
beginning of his scientifi  c 
career. His work includes 
genome-wide analyses of 
gene expression changes 
in yeast that arise from interfering with 
particular histone modifi  cations—essen-
tially decoding part of the histone code (1). 
His lab has also worked on high-reso-
lution genomic mapping of aspects of 
chromatin structure such as histone 
modifi  cations (2) and histone replacement 
dynamics (3). He has also mapped nucleo-
some positioning on a genomic scale (4), 
a study that was described as a “technical 
tour de force” (5).
With such a stellar start to his career, 
it’s no surprise that the University of 
Massachusetts snapped him up. He joined 
the faculty as an assistant professor in the 
department of Biochemistry and Molecular 
Pharmacology just four months ago. 
Recently he took time out from setting up 
his new lab to talk about his genome-wide 
adventures in chromatin structure.
EARLY START
How did you get started in science?
My father’s a scientist, so it’s an “apple 
doesn’t fall far from the tree” kind of 
situation. He’s at Harvard Medical School 
as a chemist who works in biology. I sort 
of grew up seeing science as a happy 
way to live a life. I enjoyed the way my 
dad seemed to approach the world, as 
puzzles and wanting to fi  nd out the truth, 
that sort of stuff. It seemed like an appeal-
ing way to have a career.
So you were hooked from a young age?
Yes, actually my fi  rst experience in a lab 
was during high school. I did a summer 
program called the Research Science 
Institute, and worked in a lab in George-
town (Washington, DC). Then, the fol-
lowing summer I worked in my dad’s lab. 
And when I went to university (at Har-
vard) I did an undergraduate thesis in Tom 
Maniatis’s lab, working on the NFκB 
transcription factor. I worked in Tom’s lab 
full-time in the summer holidays and 
whenever I could during the year.
Wow, you really did know early on that 
science was for you.
Yeah, there’s never been a huge question 
about it.
You did your Ph.D. with Gerald 
Crabtree at Stanford. What was 
your project?
Weidong Wang, in the lab, was just begin-
ning to clone subunits of mammalian 
ATP-dependent chromatin remodeling 
complexes, and one of the intriguing 
surprises was that actin-related proteins 
turned out to be a fairly common compo-
nent of these complexes. So I was inter-
ested in what an actin-related protein 
would be doing in a nuclear complex; 
actin wasn’t supposed to do anything in 
the nucleus, according to canon.
How did you go from looking at 
chromatin-remodeling complexes to 
looking at chromatin structure on a 
genome-wide scale?
The reason I got into genomic approaches 
to chromatin is that I thought, “Well, if 
there was some direct role for actin poly-
merization in chromatin structure, it 
wasn’t likely to be shifting a single nu-
cleosome two base 
pairs to the left.” 
Presumably what 
would be happen-
ing would be large-
scale changes in 
which nucleosomes 
are positioned or in 
some other aspect of 
chromatin structure.
I assumed, being 
at Stanford while all the microarray stuff 
was going on with Pat Brown and Ron 
Davis, that there would also be genomic 
ways to look at chromatin structure. I 
was surprised to fi  nd that there weren’t 
at the time.
So you developed these techniques when 
you moved to Harvard as a Bauer Fellow. 
What exactly is a Bauer Fellow?
It’s like faculty with training wheels. 
They’re very similar to Whitehead Fellows, 
although there are differences in detail. 
But essentially it was a fi  ve-year position 
where we had PI rights and we had fund-
ing for ourselves plus two other people. 
In other words, they would fund you to 
run a lab of three people.
One of the great things about the pro-
gram was that there were approximately 
ten fellows at a time, and they were drawn 
from a wide range of disciplines. I was the 
boring molecular biologist, but there were 
mathematicians and physicists and evolu-
tionary biologists. I collaborated with a 
number of the other fellows and learned a 
lot even from the ones I didn’t work with. 
Most extensively, we did a lot of our early 
chromatin work with Steve Altschuler and 
Lani Wu, who are mathematicians. Going 
through the process of learning to talk to 
someone who speaks such a different scien-
tifi  c language was illuminating, and I think 
it really forced me to reevaluate some of 
the hidden assumptions that are built into 
how I would usually talk about biology.
It was very stimulating working with 
people from different disciplines. It was a 
wonderful opportunity, a great position.
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Oliver Rando uses microarrays to uncover the chromatin rules of genome usage.
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SCALING UP
What is the beneﬁ  t of studying 
chromatin questions at a genomic scale?
When you look at a single gene, you 
wonder whether that gene is unusual in 
its behavior or whether that’s how all 
genes behave.
A good example of the power of 
genomic approaches is Audrey Gasch’s 
paper on environmental stress responses. 
There had been this transcriptional litera-
ture for years and years describing how 
gene A gets turned on when you put hy-
drogen peroxide on a cell, and gene B 
gets turned on by heat-shocking cells. 
This was moving forward piecemeal. 
Then, Audrey ran yeast through tons of 
different stresses and found that there 
was a core group of 800 or so genes that 
changed expression under virtually all 
stress situations. It would have required 
an almost infi  nite number of single-gene 
studies to realize that these particular 
genes behave so coherently, and that this 
group doesn’t just respond to one type of 
stress, but to all types.
Another example from our own fi  eld is 
histone H3 lysine-4 methylation. If you 
look genome wide, you fi  nd that the more 
a gene is transcribed, the more trimethyl-
ation there is at its 5′ end. So you see this 
modifi  cation all over the place. But when 
you look at the whole genome’s response 
to not having that mark—if you knock out 
the gene responsible for lysine-4 methyla-
tion—the gene expression defects are not 
that widespread. In other words, this 
methylation is happening over all active 
genes, but only a fraction of genes care 
about it. Without a genome-wide approach 
you wouldn’t easily have picked up on 
that. So, the genome-wide results help to 
frame the next set of questions about how 
histone modifi  cations work in the cell.
You use yeast for these studies. How do 
you think your work will translate 
to metazoans?
I feel like yeast is going to end up looking 
a lot like a subset of metazoan chromatin. 
In other words, a lot of the things we think 
we understand about yeast, like the role of 
K-36 methylation or where K-4 methyla-
tion happens, so far turn out to be the 
same in higher eukaryotes.
The difference is that higher eukaryotes 
also have these other systems piled on top. 
So they have additional modifi  cations. 
They have expansions of the various his-
tone families to form a wide variety of 
subunits. And so in general I think the 
basic lessons learned from yeast will apply 
to metazoans, but then there will be 
additional layers of complexity.
FUTURE PLANS
You have very recently moved to the 
University of Massachusetts. How are 
you ﬁ  nding it?
I really like my colleagues here. There’s 
a strong feeling of excitement about the 
direction of the place. There’s people 
who work on chromatin, people who 
work on RNA, people who are interested 
in transcription and nuclear structure—
all things within a stone’s throw of what 
I spend a lot of time thinking about. It’s 
a great fi  t.
What’s next for the Rando lab?
We have an idea for how to look at chroma-
tin’s secondary structure, in other words the 
30-nm fi   ber. It’s going to be technically 
challenging, and I don’t know if it’ll have 
the kind of signal-to-noise one would need 
to get anything useful out of it. But we’re 
interested in those questions.
Right now I’m thinking a lot about 
histone movement, replacement, sliding, 
etc. Most interesting is the question of 
what happens to nucleosomes during 
genomic replication, since the details 
of their behavior at the replication fork 
will really help constrain thinking about 
inheritance of chromatin states. These 
questions about histone movement are 
related to our recent work measuring 
nucleosome exchange rate during G1 arrest, 
and there is a bunch of interesting mech-
anistic follow-up to do there as well. 
One of the things we fi  nd is that nucleo-
somes are exchanging in and out of the 
promoters of most genes, but the highest 
exchange rates are found at genes that 
are regulated by ATP-dependent remod-
elers. It’s possible, then, that either dis-
sociation or reassociation or some part 
of the turnover process involves ATP-
dependent remodelers. So we’d also like 
to look into that.
We’re also planning on extending the 
histone turnover work to doing studies in 
the mouse. We’d like to make mice where 
we can ask what is the turnover rate of a 
given histone variant in the whole animal 
and in different tissues.
Lots of ﬁ  ngers in lots of pies. So your 
childhood passion for science is still 
going strong?
Yes, I’m having a blast right now. I’d like 
to be having a blast doing science in 20 
years, 50 years. I really enjoy what we’re 
able to think about and look at, and I hope 
that I manage to structure my life in such 
a way that I can continue to have fun 
doing science and thinking about problems 
well down the road.
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Decoding the histone code: microarray data 
show that mutation of histone H4 K16 (left) 
almost always switches off genes (green).
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